Vaxil Completes Oversubscribed Financing to Advance Its Cancer Immunotherapy Research and Development

VAXIL BIO (TSXV: VXL), an innovative Israeli cancer immunotherapy company, is pleased to announce the closing of an oversubscribed equity financing of $1,810,000.
As quoted in the press release:

“We are committed to advancing Vaxil’s pipeline of innovative treatments”, commented Vaxil CEO Mr. Isaac Maresky. “This financing will enable the Company to progress its research and development, and I’d like to take this opportunity to thank both existing and incoming investors for their support as we move forward.”

Click here to read the full press release.